Nuvectis Pharma, Inc. (NVCT)
24.34
+0.42
(+1.76%)
USD |
NASDAQ |
Sep 03, 16:00
24.34
0.00 (0.00%)
After-Hours: 20:00
Nuvectis Pharma Research and Development Expense (TTM) : 19.65M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.65M |
| March 31, 2026 | 18.58M |
| December 31, 2025 | 18.15M |
| September 30, 2025 | 17.56M |
| June 30, 2025 | 14.61M |
| March 31, 2025 | 13.94M |
| December 31, 2024 | 12.92M |
| September 30, 2024 | 12.69M |
| June 30, 2024 | 14.35M |
| March 31, 2024 | 15.67M |
| Date | Value |
|---|---|
| December 31, 2023 | 15.38M |
| September 30, 2023 | 15.51M |
| June 30, 2023 | 15.55M |
| March 31, 2023 | 13.79M |
| December 31, 2022 | 13.23M |
| September 30, 2022 | 9.974M |
| June 30, 2022 | 9.61M |
| March 31, 2022 | 11.35M |
| December 31, 2021 | 9.545M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Decoy Therapeutics, Inc. | 2.230M |
| Unicycive Therapeutics, Inc. | 9.609M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |